Ex-Gala­pa­gos med­ical chief heads to uniQure; Mar­tin Mack­ay lines up Rally­bio suc­ces­sor

→ For­mer Gala­pa­gos ex­ec Walid Abi-Saab has found a change in scenery, join­ing gene ther­a­py biotech uniQure as CMO. He left Shire in 2017 to be­come med­ical chief at Gala­pa­gos, whose part­ner­ship with Gilead on fil­go­tinib fell apart and is un­der­go­ing a re­build with CEO Paul Stof­fels. Abi-Saab an­nounced his re­tire­ment at Gala­pa­gos in De­cem­ber along­side CBO An­dré Hoeke­ma; CFO and COO Bart Fil­ius fol­lowed them out the door in ear­ly May. With Abi-Saab’s ap­point­ment, Ri­car­do Dol­metsch’s job ti­tle changes from R&D chief to pres­i­dent and CSO at uniQure, which re­leased Phase I/II da­ta for its Hunt­ing­ton’s gene ther­a­py AMT-130 that flum­moxed many ob­servers. Stifel’s Paul Mat­teis la­beled the da­ta drop “very con­fus­ing” as uniQure’s stock $QURE took a dive.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.